EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

Tomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, Tetsushi Izuchi, Koji Suzuki, Koki Otake, Yoshinori Yasuda, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara und 15 weitere

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03733-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Tomoko Kobayashi und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, B7-H1 Antigen, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nagoya University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti-programmed cell death-1 (ligand-1) antibody [PD-(L)1-Ab] can cause destructive thyroiditis and/or hypothyroidism. In addition, tyrosine kinase inhibitors (TKIs) frequently induce hypothyroidism. The aim of this prospective study is to examine the incidence and clinical characteristics of thyroid dysfunction induced by combination therapy of a PD-(L)1-Ab and TKI [PD-(L)1-Ab/TKI].

Methods

A total of 757 patients treated with PD-(L)1-Ab or PD-(L)1-Ab/TKI were evaluated for anti-thyroid antibodies (ATAs) at baseline and for thyroid function for 48 weeks after treatment initiation and then observed until the last visit.

Results

The cumulative incidences of destructive thyroiditis [4/23 (17.4%) vs. 45/734 (6.1%) patients, p < 0.001], isolated hypothyroidism [10/23 (43.5%) vs. 29/734 (4.0%) patients, p < 0.001], and all thyroid dysfunction [14/23 (60.9%) vs. 74/734 (10.1%) patients, p < 0.001] were significantly higher in the PD-(L)1-Ab/TKI group than PD-(L)1-Ab group, respectively. All patients positive for ATAs at baseline developed thyroid dysfunction after PD-(L)1-Ab/TKI treatment, a significantly higher incidence than that in those negative for ATAs at baseline [4/4 (100%) vs. 10/19 (52.6%) patients, p = 0.026].

Conclusions

The addition of TKIs increased the risk of thyroid dysfunction induced by PD-(L)1-Ab, with the risk being higher in patients positive for baseline ATAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsB7-H1 AntigenImmune Checkpoint InhibitorsHumansMaleFemaleProspective StudiesMiddle AgedAgedThyroid DiseasesAdultIncidenceNeoplasmsAged, 80 and overHypothyroidismTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

HypothyroidismPD-1PD-L1TKIThyroiditisirAE

Substanzen

Protein Kinase InhibitorsB7-H1 AntigenImmune Checkpoint InhibitorsCD274 protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.
  • Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan. iwama.shintaro.m1@f.mail.nagoya-u.ac.jp.
  • Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
  • Physical Fitness and Sports, Research Center of Health, Nagoya University, Nagoya, Japan.
  • Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Förderung

  • Nagoya University

Zitieren

APA

Kobayashi, T., Iwama, S., Yamagami, A., Izuchi, T., Suzuki, K., Otake, K., Yasuda, Y., Ando, M., Onoue, T., Miyata, T., Sugiyama, M., Hagiwara, D., Suga, H., Banno, R., Hase, T., Nishio, N., Mori, S., Shimokata, T., Sano, T., …, & Arima, H. (2024). Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03733-2

Vancouver

Kobayashi T, Iwama S, Yamagami A, Izuchi T, Suzuki K, Otake K, et al. Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03733-2

BibTeX
@article{Kobayashi2024,
  author = {Kobayashi, Tomoko and Iwama, Shintaro and Yamagami, Ayana and Izuchi, Tetsushi and Suzuki, Koji and Otake, Koki and Yasuda, Yoshinori and Ando, Masahiko and Onoue, Takeshi and Miyata, Takashi and Sugiyama, Mariko and Hagiwara, Daisuke and Suga, Hidetaka and Banno, Ryoichi and Hase, Tetsunari and Nishio, Naoki and Mori, Shoichiro and Shimokata, Tomoya and Sano, Tomoyasu and Niimi, Kaoru and Yoshikawa, Nobuhisa and Akamatsu, Shusuke and Ando, Yuichi and Akiyama, Masashi and Sone, Michihiko and Ishii, Makoto and Arima, Hiroshi},
  title = {Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03733-2}
}
Kostenlos starten →